Trial Outcomes & Findings for First-in-man Trial of NNC0142-0002 in Patients With Rheumatoid Arthritis (NCT NCT00927927)

Last Updated: 2016-10-03

Results Overview

Adverse event: any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product, and which does not necessarily have a causal relationship with this treatment. Serious AE: AE that at any dose level resulted in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalization, a persistent/significant disability/incapacity, a congenital anomaly or birth defect, or an important medical event that may jeopardize the subject and require medical or surgical intervention.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

65 participants

Primary outcome timeframe

Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity.

Results posted on

2016-10-03

Participant Flow

The trial was conducted at one site in Germany.

A total of 65 subjects were randomised, but only 64 subjects were exposed to trial product. One subject withdrew consent after being randomised but before receiving any trial product.

Participant milestones

Participant milestones
Measure	SD 0.0002 mg/kg Subjects were dosed once with NNC0142-0002 at a dose of 0.0002 mg/kg	SD 0.0012 mg/kg Subjects were dosed once with NNC0142-0002 at a dose of 0.0012 mg/kg	SD 0.007 mg/kg Subjects were dosed once with NNC0142-0002 at a dose of 0.007 mg/kg	SD 0.035 mg/kg Subjects were dosed once with NNC0142-0002 at a dose of 0.035 mg/kg	SD 0.175 mg/kg Subjects were dosed once with NNC0142-0002 at a dose of 0.175 mg/kg	SD 0.7 mg/kg Subjects were dosed once with NNC0142-0002 at a dose of 0.7 mg/kg	SD 2.5 mg/kg Subjects were dosed once with NNC0142-0002 at a dose of 2.5 mg/kg	SD 7.5 mg/kg Subjects were dosed once with NNC0142-0002 at a dose of 7.5 mg/kg	SD Placebo Subjects were dosed once with placebo	MD 0.02 mg/kg Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.02 mg/kg	MD 0.3 mg/kg Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.3 mg/kg	MD 1.0 mg/kg Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.0 mg/kg	MD 1.6 mg/kg Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.6 mg/kg	MD 4.0 mg/kg Subjects were injected biweekly four times with NNC0142-0002 at a dose of 4.0 mg/kg	MD Placebo Subjects were injected biweekly four times with placebo
Overall Study STARTED	3	3	3	3	3	3	3	3	8	3	5	6	5	5	9
Overall Study Exposed	3	3	3	3	3	3	3	3	8	3	5	5	5	5	9
Overall Study COMPLETED	3	3	3	3	3	3	3	1	8	3	5	4	5	5	9
Overall Study NOT COMPLETED	0	0	0	0	0	0	0	2	0	0	0	2	0	0	0

Reasons for withdrawal

Reasons for withdrawal
Measure	SD 0.0002 mg/kg Subjects were dosed once with NNC0142-0002 at a dose of 0.0002 mg/kg	SD 0.0012 mg/kg Subjects were dosed once with NNC0142-0002 at a dose of 0.0012 mg/kg	SD 0.007 mg/kg Subjects were dosed once with NNC0142-0002 at a dose of 0.007 mg/kg	SD 0.035 mg/kg Subjects were dosed once with NNC0142-0002 at a dose of 0.035 mg/kg	SD 0.175 mg/kg Subjects were dosed once with NNC0142-0002 at a dose of 0.175 mg/kg	SD 0.7 mg/kg Subjects were dosed once with NNC0142-0002 at a dose of 0.7 mg/kg	SD 2.5 mg/kg Subjects were dosed once with NNC0142-0002 at a dose of 2.5 mg/kg	SD 7.5 mg/kg Subjects were dosed once with NNC0142-0002 at a dose of 7.5 mg/kg	SD Placebo Subjects were dosed once with placebo	MD 0.02 mg/kg Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.02 mg/kg	MD 0.3 mg/kg Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.3 mg/kg	MD 1.0 mg/kg Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.0 mg/kg	MD 1.6 mg/kg Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.6 mg/kg	MD 4.0 mg/kg Subjects were injected biweekly four times with NNC0142-0002 at a dose of 4.0 mg/kg	MD Placebo Subjects were injected biweekly four times with placebo
Overall Study Withdrawal by Subject	0	0	0	0	0	0	0	2	0	0	0	2	0	0	0

Baseline Characteristics

First-in-man Trial of NNC0142-0002 in Patients With Rheumatoid Arthritis

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	SD 0.0002 mg/kg n=3 Participants Subjects were dosed once with NNC0142-0002 at a dose of 0.0002 mg/kg	SD 0.0012 mg/kg n=3 Participants Subjects were dosed once with NNC0142-0002 at a dose of 0.0012 mg/kg	SD 0.007 mg/kg n=3 Participants Subjects were dosed once with NNC0142-0002 at a dose of 0.007 mg/kg	SD 0.035 mg/kg n=3 Participants Subjects were dosed once with NNC0142-0002 at a dose of 0.035 mg/kg	SD 0.175 mg/kg n=3 Participants Subjects were dosed once with NNC0142-0002 at a dose of 0.175 mg/kg	SD 0.7 mg/kg n=3 Participants Subjects were dosed once with NNC0142-0002 at a dose of 0.7 mg/kg	SD 2.5 mg/kg n=3 Participants Subjects were dosed once with NNC0142-0002 at a dose of 2.5 mg/kg	SD 7.5 mg/kg n=3 Participants Subjects were dosed once with NNC0142-0002 at a dose of 7.5 mg/kg	SD Placebo n=8 Participants Subjects were dosed once with placebo	MD 0.02 mg/kg n=3 Participants Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.02 mg/kg	MD 0.3 mg/kg n=5 Participants Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.3 mg/kg	MD 1.0 mg/kg n=5 Participants Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.0 mg/kg	MD 1.6 mg/kg n=5 Participants Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.6 mg/kg	MD 4.0 mg/kg n=5 Participants Subjects were injected biweekly four times with NNC0142-0002 at a dose of 4.0 mg/kg	MD Placebo n=9 Participants Subjects were injected biweekly four times with placebo	Total n=64 Participants Total of all reporting groups
Age, Continuous	63.0 participants STANDARD_DEVIATION 7.9 • n=5 Participants	60.7 participants STANDARD_DEVIATION 8.1 • n=7 Participants	66.7 participants STANDARD_DEVIATION 8.1 • n=5 Participants	58.3 participants STANDARD_DEVIATION 5.1 • n=4 Participants	58.7 participants STANDARD_DEVIATION 3.1 • n=21 Participants	52.7 participants STANDARD_DEVIATION 11.0 • n=8 Participants	49.0 participants STANDARD_DEVIATION 10.8 • n=8 Participants	69.0 participants STANDARD_DEVIATION 4.6 • n=24 Participants	52.8 participants STANDARD_DEVIATION 7.8 • n=42 Participants	55.3 participants STANDARD_DEVIATION 5.0 • n=42 Participants	56.4 participants STANDARD_DEVIATION 9.4 • n=42 Participants	58.4 participants STANDARD_DEVIATION 5.5 • n=42 Participants	53.0 participants STANDARD_DEVIATION 17.9 • n=36 Participants	48.2 participants STANDARD_DEVIATION 7.7 • n=36 Participants	53.7 participants STANDARD_DEVIATION 11.0 • n=24 Participants	56.0 participants STANDARD_DEVIATION 9.8 • n=135 Participants
Sex: Female, Male Female	3 Participants n=5 Participants	2 Participants n=7 Participants	3 Participants n=5 Participants	3 Participants n=4 Participants	2 Participants n=21 Participants	2 Participants n=8 Participants	3 Participants n=8 Participants	1 Participants n=24 Participants	6 Participants n=42 Participants	2 Participants n=42 Participants	5 Participants n=42 Participants	3 Participants n=42 Participants	4 Participants n=36 Participants	2 Participants n=36 Participants	8 Participants n=24 Participants	49 Participants n=135 Participants
Sex: Female, Male Male	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	1 Participants n=8 Participants	0 Participants n=8 Participants	2 Participants n=24 Participants	2 Participants n=42 Participants	1 Participants n=42 Participants	0 Participants n=42 Participants	2 Participants n=42 Participants	1 Participants n=36 Participants	3 Participants n=36 Participants	1 Participants n=24 Participants	15 Participants n=135 Participants

PRIMARY outcome

Timeframe: Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity.

Population: All randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.

Outcome measures

Outcome measures
Measure	SD 0.0002 mg/kg n=3 Participants Subjects were dosed once with NNC0142-0002 at a dose of 0.0002 mg/kg	SD 0.0012 mg/kg n=3 Participants Subjects were dosed once with NNC0142-0002 at a dose of 0.0012 mg/kg	SD 0.007 mg/kg n=3 Participants Subjects were dosed once with NNC0142-0002 at a dose of 0.007 mg/kg	SD 0.035 mg/kg n=3 Participants Subjects were dosed once with NNC0142-0002 at a dose of 0.035 mg/kg	SD 0.175 mg/kg n=3 Participants Subjects were dosed once with NNC0142-0002 at a dose of 0.175 mg/kg	SD 0.7 mg/kg n=3 Participants Subjects were dosed once with NNC0142-0002 at a dose of 0.7 mg/kg	SD 2.5 mg/kg n=3 Participants Subjects were dosed once with NNC0142-0002 at a dose of 2.5 mg/kg	SD 7.5 mg/kg n=3 Participants Subjects were dosed once with NNC0142-0002 at a dose of 7.5 mg/kg	SD Placebo n=8 Participants Subjects were dosed once with placebo	MD 0.02 mg/kg n=3 Participants Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.02 mg/kg	MD 0.3 mg/kg n=5 Participants Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.3 mg/kg	MD 1.0 mg/kg n=5 Participants Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.0 mg/kg	MD 1.6 mg/kg n=5 Participants Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.6 mg/kg	MD 4.0 mg/kg n=5 Participants Subjects were injected biweekly four times with NNC0142-0002 at a dose of 4.0 mg/kg	MD Placebo n=9 Participants Subjects were injected biweekly four times with placebo
Frequency of Adverse Events Adverse events	5 events	4 events	3 events	4 events	1 events	8 events	6 events	3 events	9 events	4 events	8 events	13 events	10 events	14 events	9 events
Frequency of Adverse Events Serious AE	0 events	0 events	0 events	0 events	0 events	1 events	0 events	1 events	0 events	0 events	0 events	0 events	0 events	0 events	0 events

SECONDARY outcome

Timeframe: Data were collected from 0 hours to at least Day 43 (SD cohorts) and Day 85 (MD cohorts), and until the receptor occupancy was confirmed below the cut-off level for receptor positivity.

Population: All randomised subjects exposed to at least one dose of NNC0142-0002 or placebo. Serum drug concentrations after dosing with less than 0.175 mg/kg (SD cohorts) and 0.3 mg/kg (MD cohorts) were below the lower limit of quantification.

Systemic exposure to NNC0142-0002.

Outcome measures

Outcome measures
Measure	SD 0.0002 mg/kg n=3 Participants Subjects were dosed once with NNC0142-0002 at a dose of 0.0002 mg/kg	SD 0.0012 mg/kg n=3 Participants Subjects were dosed once with NNC0142-0002 at a dose of 0.0012 mg/kg	SD 0.007 mg/kg n=3 Participants Subjects were dosed once with NNC0142-0002 at a dose of 0.007 mg/kg	SD 0.035 mg/kg n=3 Participants Subjects were dosed once with NNC0142-0002 at a dose of 0.035 mg/kg	SD 0.175 mg/kg n=3 Participants Subjects were dosed once with NNC0142-0002 at a dose of 0.175 mg/kg	SD 0.7 mg/kg n=3 Participants Subjects were dosed once with NNC0142-0002 at a dose of 0.7 mg/kg	SD 2.5 mg/kg n=3 Participants Subjects were dosed once with NNC0142-0002 at a dose of 2.5 mg/kg	SD 7.5 mg/kg n=3 Participants Subjects were dosed once with NNC0142-0002 at a dose of 7.5 mg/kg	SD Placebo n=8 Participants Subjects were dosed once with placebo	MD 0.02 mg/kg n=3 Participants Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.02 mg/kg	MD 0.3 mg/kg n=5 Participants Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.3 mg/kg	MD 1.0 mg/kg n=5 Participants Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.0 mg/kg	MD 1.6 mg/kg n=5 Participants Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.6 mg/kg	MD 4.0 mg/kg n=5 Participants Subjects were injected biweekly four times with NNC0142-0002 at a dose of 4.0 mg/kg	MD Placebo n=9 Participants Subjects were injected biweekly four times with placebo
Area Under the Concentration-time Curve (AUC)	NA microgram×h/mL Geometric Coefficient of Variation NA Exposure was below lower level of quantification.	NA microgram×h/mL Geometric Coefficient of Variation NA Exposure was below lower level of quantification.	NA microgram×h/mL Geometric Coefficient of Variation NA Exposure was below lower level of quantification.	NA microgram×h/mL Geometric Coefficient of Variation NA Exposure was below lower level of quantification.	91 microgram×h/mL Geometric Coefficient of Variation 306.6 • Interval 306.6 to	4229 microgram×h/mL Geometric Coefficient of Variation 12.7 • Interval 12.7 to	16616 microgram×h/mL Geometric Coefficient of Variation 35.2 • Interval 35.2 to	87461 microgram×h/mL Geometric Coefficient of Variation 29.9 • Interval 29.9 to	NA microgram×h/mL Geometric Coefficient of Variation NA AUC was not calculated as subjects were not exposed to NNC0142-0002.	NA microgram×h/mL Geometric Coefficient of Variation NA Exposure was below lower level of quantification.	4034 microgram×h/mL Geometric Coefficient of Variation 62.8 • Interval 62.8 to	21883 microgram×h/mL Geometric Coefficient of Variation 29.6 • Interval 29.6 to	30212 microgram×h/mL Geometric Coefficient of Variation 25.4 • Interval 25.4 to	83307 microgram×h/mL Geometric Coefficient of Variation 38.3 • Interval 38.3 to	NA microgram×h/mL Geometric Coefficient of Variation NA AUC was not calculated as subjects were not exposed to NNC0142-0002.

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	SD 0.0002 mg/kg n=3 participants at risk Subjects were dosed once with NNC0142-0002 at a dose of 0.0002 mg/kg	MD 0.02 mg/kg n=3 participants at risk Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.02 mg/kg	SD 0.0012 mg/kg n=3 participants at risk Subjects were dosed once with NNC0142-0002 at a dose of 0.0012 mg/kg	SD 0.007 mg/kg n=3 participants at risk Subjects were dosed once with NNC0142-0002 at a dose of 0.007 mg/kg	SD 0.035 mg/kg n=3 participants at risk Subjects were dosed once with NNC0142-0002 at a dose of 0.035 mg/kg	SD 0.175 mg/kg n=3 participants at risk Subjects were dosed once with NNC0142-0002 at a dose of 0.175 mg/kg	SD 0.7 mg/kg n=3 participants at risk Subjects were dosed once with NNC0142-0002 at a dose of 0.7 mg/kg	SD 2.5 mg/kg n=3 participants at risk Subjects were dosed once with NNC0142-0002 at a dose of 2.5 mg/kg	SD 7.5 mg/kg n=3 participants at risk Subjects were dosed once with NNC0142-0002 at a dose of 7.5 mg/kg	SD Placebo n=8 participants at risk Subjects were dosed once with placebo	MD 0.3 mg/kg n=5 participants at risk Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.3 mg/kg	MD 1.0 mg/kg n=5 participants at risk Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.0 mg/kg	MD 1.6 mg/kg n=5 participants at risk Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.6 mg/kg	MD 4.0 mg/kg n=5 participants at risk Subjects were injected biweekly four times with NNC0142-0002 at a dose of 4.0 mg/kg	MD Placebo n=9 participants at risk Subjects were injected biweekly four times with placebo
General disorders Fatigue	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	33.3% 1/3 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/8 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/9 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Injury, poisoning and procedural complications Femoral neck fracture	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	33.3% 1/3 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/8 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/9 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.

Other adverse events

Other adverse events
Measure	SD 0.0002 mg/kg n=3 participants at risk Subjects were dosed once with NNC0142-0002 at a dose of 0.0002 mg/kg	MD 0.02 mg/kg n=3 participants at risk Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.02 mg/kg	SD 0.0012 mg/kg n=3 participants at risk Subjects were dosed once with NNC0142-0002 at a dose of 0.0012 mg/kg	SD 0.007 mg/kg n=3 participants at risk Subjects were dosed once with NNC0142-0002 at a dose of 0.007 mg/kg	SD 0.035 mg/kg n=3 participants at risk Subjects were dosed once with NNC0142-0002 at a dose of 0.035 mg/kg	SD 0.175 mg/kg n=3 participants at risk Subjects were dosed once with NNC0142-0002 at a dose of 0.175 mg/kg	SD 0.7 mg/kg n=3 participants at risk Subjects were dosed once with NNC0142-0002 at a dose of 0.7 mg/kg	SD 2.5 mg/kg n=3 participants at risk Subjects were dosed once with NNC0142-0002 at a dose of 2.5 mg/kg	SD 7.5 mg/kg n=3 participants at risk Subjects were dosed once with NNC0142-0002 at a dose of 7.5 mg/kg	SD Placebo n=8 participants at risk Subjects were dosed once with placebo	MD 0.3 mg/kg n=5 participants at risk Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.3 mg/kg	MD 1.0 mg/kg n=5 participants at risk Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.0 mg/kg	MD 1.6 mg/kg n=5 participants at risk Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.6 mg/kg	MD 4.0 mg/kg n=5 participants at risk Subjects were injected biweekly four times with NNC0142-0002 at a dose of 4.0 mg/kg	MD Placebo n=9 participants at risk Subjects were injected biweekly four times with placebo
Investigations Alanine aminotransferase increased	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	12.5% 1/8 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/9 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Ear and labyrinth disorders Vertigo	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/8 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	11.1% 1/9 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Eye disorders Lacrimation increased	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	33.3% 1/3 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/8 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/9 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Gastrointestinal disorders Abdominal pain upper	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	33.3% 1/3 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	33.3% 1/3 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/8 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/9 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Gastrointestinal disorders Diarrhoea	33.3% 1/3 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	33.3% 1/3 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	12.5% 1/8 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	20.0% 1/5 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/9 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Gastrointestinal disorders Flatulence	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	33.3% 1/3 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/8 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/9 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Gastrointestinal disorders Nausea	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	33.3% 1/3 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/8 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	11.1% 1/9 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Gastrointestinal disorders Stomatitis	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/8 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	20.0% 1/5 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/9 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Gastrointestinal disorders Vomiting	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/8 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	20.0% 1/5 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	11.1% 1/9 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
General disorders Fatigue	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/8 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	20.0% 1/5 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/9 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
General disorders Injection site pain	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	12.5% 1/8 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/9 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
General disorders Oedema peripheral	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/8 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	11.1% 1/9 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Hepatobiliary disorders Cholelithiasis	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	33.3% 1/3 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/8 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/9 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Infections and infestations Bronchitis	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/8 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	20.0% 1/5 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	40.0% 2/5 • Number of events 2 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/9 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Infections and infestations Diverticulitis	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/8 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	20.0% 1/5 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/9 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Infections and infestations Gastroenteritis	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	33.3% 1/3 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/8 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	20.0% 1/5 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	20.0% 1/5 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/9 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Infections and infestations Nasopharyngitis	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	33.3% 1/3 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	33.3% 1/3 • Number of events 2 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	100.0% 3/3 • Number of events 3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	66.7% 2/3 • Number of events 2 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	25.0% 2/8 • Number of events 2 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	60.0% 3/5 • Number of events 3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	80.0% 4/5 • Number of events 5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	60.0% 3/5 • Number of events 4 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	40.0% 2/5 • Number of events 3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	11.1% 1/9 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Infections and infestations Oral herpes	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	12.5% 1/8 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/9 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Infections and infestations Paronychia	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	12.5% 1/8 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/9 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Injury, poisoning and procedural complications Incorrect dose administered	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/8 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	20.0% 1/5 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/9 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Injury, poisoning and procedural complications Injury	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/8 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	20.0% 1/5 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/9 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Investigations Blood creatine phosphokinase increased	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/8 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	11.1% 1/9 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Investigations Epstein-Barr virus antibody positive	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	33.3% 1/3 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/8 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/9 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	12.5% 1/8 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/9 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	33.3% 1/3 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/8 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	20.0% 1/5 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/9 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	33.3% 1/3 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/8 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/9 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Musculoskeletal and connective tissue disorders Rheumatoid arthritis	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	66.7% 2/3 • Number of events 2 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/8 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	20.0% 1/5 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	20.0% 1/5 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/9 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Nervous system disorders Dizziness	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	33.3% 1/3 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/8 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/9 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Nervous system disorders Headache	66.7% 2/3 • Number of events 4 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	33.3% 1/3 • Number of events 2 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	33.3% 1/3 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	33.3% 1/3 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	33.3% 1/3 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	33.3% 1/3 • Number of events 2 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	12.5% 1/8 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	20.0% 1/5 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	20.0% 1/5 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	20.0% 1/5 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	60.0% 3/5 • Number of events 4 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	11.1% 1/9 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Nervous system disorders Migraine	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/8 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	20.0% 1/5 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	20.0% 1/5 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/9 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Nervous system disorders Sciatica	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/8 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	11.1% 1/9 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Psychiatric disorders Depression	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/8 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	20.0% 1/5 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/9 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	33.3% 1/3 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/8 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/9 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Skin and subcutaneous tissue disorders Rash	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/8 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	40.0% 2/5 • Number of events 3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/9 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Skin and subcutaneous tissue disorders Skin irritation	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/8 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	11.1% 1/9 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Vascular disorders Haematoma	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/8 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	20.0% 1/5 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/9 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.
Vascular disorders Hypertension	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/3 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	33.3% 1/3 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/8 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/5 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	20.0% 1/5 • Number of events 1 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.	0.00% 0/9 • Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity. The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.

Additional Information

Public Access to Clinical Trials

Novo Nordisk A/S

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee Novo Nordisk reserves the right to defer data release until specified milestones, e.g. availability of a clinical trial report. Novo Nordisk reserves the right to postpone publication and/or communication for short period to protect intellectual property. Novo Nordisk reserves the right to prior review of site-specific publications and to ask for deferment of publication of individual site results until after the primary manuscript is accepted for publication.
Publication restrictions are in place

Restriction type: OTHER